EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence

Qiongxiao Huang, Jing Zhu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112724 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Qiongxiao Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hang…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, T-Lymphocytes, Regulatory, Immunotherapy, Adoptive. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 248 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune diseases (ADs) are among the most significant health complications, with their incidence rising in recent years. Type 1 diabetes (T1D), an AD, targets the insulin-producing β cells in the pancreas, leading to chronic insulin deficiency in genetically susceptible individuals. Regulatory immune cells, particularly T-cells (Tregs), have been shown to play a crucial role in the pathogenesis of diabetes by modulating immune responses. In diabetic patients, Tregs often exhibit diminished effectiveness due to various factors, such as instability in forkhead box P3 (Foxp3) expression or abnormal production of the proinflammatory cytokine interferon-gamma (IFN-γ) by autoreactive T-cells. Consequently, Tregs represent a potential therapeutic target for diabetes treatment. Building on the successful clinical outcomes of chimeric antigen receptor (CAR) T-cell therapy in cancer treatment, particularly in leukemias, the concept of designing and utilizing CAR Tregs for ADs has emerged. This review summarizes the findings on Treg targeting in T1D and discusses the benefits and limitations of this treatment approach for patients suffering from T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1T-Lymphocytes, RegulatoryImmunotherapy, AdoptiveHumansAnimalsReceptors, Chimeric AntigenInsulin-Secreting CellsForkhead Transcription Factors

Stichwörter der Autor:innen

Autoimmune diseaseCell therapyDiabetesTreg therapy

Substanzen

Receptors, Chimeric AntigenForkhead Transcription Factors

Autor:innen und Institutionen

  • Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
  • Center for Reproductive Medicine, Department of Reproductive Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China. Electronic ad…

Zitieren

APA

Huang, Q., & Zhu, J. (2024). Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112724

Vancouver

Huang Q, Zhu J. Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112724

BibTeX
@article{Huang2024,
  author = {Huang, Qiongxiao and Zhu, Jing},
  title = {Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112724}
}
Kostenlos starten →